X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Experimental Tardive Dyskinesia Drug NBI-98854 Hits Mark in Phase 3

Yuvraj_pawp by Yuvraj_pawp
24th October 2015
in Clinical Trials

NBI-98854, an experimental drug for tardive dyskinesia being developed by Neurocrine Biosciences, led to a statistically significant reduction in symptoms of the movement disorder in a phase 3, placebo-controlled trial called Kinect 3, the company announced Thursday.

NBI-98854 is a novel, highly selective inhibitor of the vesicular monoamine transporter 2 (VMAT2) protein that modulates neuronal dopamine levels. It is designed to provide “low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive monoamine depletion,” the company notes in a news release.

“Modulation of neuronal dopamine levels in diseases such as tardive dyskinesia, Tourette syndrome, Huntington’s chorea, schizophrenia, and tardive dystonia, which are characterized, in part, by a hyperdopaminergic state, should provide symptomatic benefits for patients with these diseases,” they say.

The US Food and Drug Administration (FDA) granted NBI-98854 Breakthrough Therapy Designation for the treatment of tardive dyskinesia in October 2014.

The Kinect 3 study involved 234 patients with moderate to severe tardive dyskinesia with underlying schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder. Patients were randomly allocated to receive either placebo or NBI-98854 once daily at a dose of 40 mg or 80 mg for 6 weeks. From weeks 6 through 48, during the open-label portion of the trial, all patients were taking NBI-98854 (40 or 80 mg once daily).

According to the company, there was a significant difference favoring NBI-98854 in the prespecified primary efficacy end point ― change from baseline in the Abnormal Involuntary Movement Scale (AIMS) at week 6 in the 80-mg, once-daily dosing group compared with the placebo group.

The AIMS ratings at week 6 for the 80-mg, once-daily NBI-98854 intention-to-treat population was reduced 3.1 points more than for the patients receiving placebo (P < .0001).

NBI-98854 was generally well tolerated during the 6-week, placebo-controlled treatment period. The frequency of adverse events was similar among all treatment groups, and treatment-emergent adverse effects were consistent with those of prior studies, the company says.

At baseline, patients had “minimal symptoms” on the Barnes Akathisia Ratings Scale for akathisia and the Simpson-Angus Scale for parkinsonism, and there was no worsening during 6 weeks of treatment.

No drug-drug interactions were identified in study patients, who were taking a wide range of psychotropic and other concomitant medications.

“We are very pleased with the outstanding efficacy and side effect profile demonstrated by NBI-98854 in the Kinect 3 study. The efficacy data from this pivotal phase 3 study completes our placebo-controlled dataset for NBI-98854 in tardive dyskinesia,” Kevin C. Gorman, PhD, Neurocrine president and chief executive officer, said in the release.

“We will now turn our focus to completing the open-label safety portion of the studies in tardive dyskinesia patients and compiling the data for both doses of NBI-98854 to be included in the New Drug Application we intend to file with the FDA in 2016,” he said.

Previous Post

MediciNova to Initiate Clinical Trial of MN-001 (tipelukast) in IPF

Next Post

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Related Posts

Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Clinical Trials

Cancer Clinical Trials Get A Brand New Platform In Melbourne

3rd November 2022
Clinical Trials

UK Clinical Trials Have Plummeted In The Past Five Years

22nd October 2022
Clinical Trials

Pistoia Alliance To Study Clinical Trial Ecology Effect

14th October 2022
Next Post

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Latest News

FDA Approvals

NHS Acquires Potentially Lifesaving Breast Cancer Medication

9th November 2022
Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In